Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
City of Hope Medical Center
Dana-Farber Cancer Institute
Weill Medical College of Cornell University
National Institutes of Health Clinical Center (CC)
University of Miami
Universitätsklinikum Hamburg-Eppendorf
Arog Pharmaceuticals, Inc.
University of Nebraska
University of Nebraska
Arog Pharmaceuticals, Inc.
University of Nebraska
Goethe University
Therapeutic Advances in Childhood Leukemia Consortium
Children's Oncology Group
Therapeutic Advances in Childhood Leukemia Consortium
Medical College of Wisconsin
Therapeutic Advances in Childhood Leukemia Consortium
Milton S. Hershey Medical Center
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
Barbara Ann Karmanos Cancer Institute
Washington University School of Medicine
Washington University School of Medicine
Children's Oncology Group
National Cancer Institute (NCI)
Stanford University
Washington University School of Medicine
Washington University School of Medicine
Alliance for Clinical Trials in Oncology
Washington University School of Medicine
National Cancer Institute (NCI)
Children's Hospital of Philadelphia